Teplizumab for delaying the onset of stage 3 type 1 diabetes in people 8 years and over with stage 2 type 1 diabetes [ID6259]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 16 July 2025
Type 2 diabetes in adults: management (medicines update)Status:In developmentProgramme:NICE guidelineExpected publication date: 30 July 2025
Semaglutide for treating type 2 diabetes [ID1450]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Dulaglutide for treating type 2 diabetes in children and young people [TSID10660]Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Ranibizumab port delivery system for treating diabetic macular oedema [ID6137]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Insulin icodec for treating type 2 diabetes [ID6175]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Aflibercept for untreated diabetic macular oedema [TSID10621]Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Semaglutide for treating type 2 diabetes and associated peripheral arterial disease [TSID11791]Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Cardiometabolic disease prevention and treatment guidelinesStatus:In developmentProgramme:NICE HubExpected publication date: TBC
Canagliflozin for treating type 2 diabetes in people 10 to 17 years [TSID11888]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Basal insulin icodec–semaglutide for treating type 2 diabetes inadequately controlled with daily basal insulin [TSID11940]Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Insulin efsitora alfa for treating type 2 diabetes in people on daily insulin injections [ID6499]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Insulin efsitora alfa for treating type 1 diabetes in people on multiple daily insulin injections [ID6498]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Tirzepatide for treating type 2 diabetes in people 10 to 17 years [TSID12131]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC